Suzhou Transcenta Therapeutics Co., Ltd.

218 Xinghu Street, Biobay, Bldg. B6-501, Suzhou, 江苏省, China

Clinical Trials

4 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

77.8%

Phase 2

11.1%

Phase 3

11.1%

Trial Status Distribution

Active, not recruiting

22.2%

Completed

22.2%

Not yet recruiting

22.2%

Recruiting

11.1%

Terminated

22.2%

Clinical Trials

Trials sponsored by this organization (9)

Study of TST002 Injection in Postmenopausal Women With Osteoporosis or Low Bone Mass

Phase 2

Not yet recruiting

interventional

Oct 2026110 participants

Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

Phase 3

Not yet recruiting

interventional

Jun 2026820 participants

A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

Phase 1

Active, not recruiting

interventional

Feb 2023111 participants

Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Terminated

interventional

Jun 202119 participants

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

interventional

Aug 2020320 participants

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Phase 1

Active, not recruiting

interventional

May 2020150 participants

A Study of MSB0254 Injection in Advanced Solid Tumors

Phase 1

Terminated

interventional

Apr 202025 participants

A Study of MSB2311 in Advanced Solid Tumors

Phase 1

Completed

interventional

Aug 201842 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations